Literature DB >> 22714910

Detection of new biallelic polymorphisms in the human MxA gene.

Tam Tran Thi Duc1, Frédéric Farnir, Charles Michaux, Daniel Desmecht, Anne Cornet.   

Abstract

The interferon-inducible human MxA protein plays an important role in innate defense against an array of viruses. One might expect allelic diversity at the MxA locus to influence the timing and magnitude of its expression or even the range of viruses whose biological cycle is inhibited by the encoded product. Here we have collected 267 samples of genomic DNA from three distinct populations (European, Asian, and African) and have systematically sequenced the promoter of the MxA gene and its 17 exons in order to inventory its allelic variants. Eighteen single-nucleotide polymorphisms were detected, four of which had never been identified before. Two of these, located in the promoter (at positions -309 and -101 respectively), might affect the MxA expression pattern. The other two result in substitutions (Gly255Glu and Val268Met) in the protein's N-terminal region that might directly affect its antiviral function.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22714910      PMCID: PMC7088644          DOI: 10.1007/s11033-012-1708-7

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


Introduction

The Mx proteins of vertebrates are high-molecular-weight dynamin-like proteins encoded, according to the species, by two or three distinct genes whose expression depends strictly on type-1 and type-3 interferons [1]. They consist of three domains: an N-terminal GTPase domain that binds and hydrolyzes GTP (G domain), a middle domain that mediates self-assembly and oligomerization (MD), and a C-terminal GTPase effector domain involved in self-assembly (GED) [2]. Some isoforms are able to inhibit the life cycle of one or several viruses and are thus components of innate immune response. The ability of an Mx protein to act against a virus depends on the nature of its GED domain, probably involved in recognizing viral targets [3]. Among the Mx proteins known to exert antiviral activity, the human MxA protein displays the broadest antiviral spectrum, inhibiting the life cycles of viruses belonging to a diverse range of families: Orthomyxoviridae, Paramyxoviridae, Rhabdoviridae, Bunyaviridae, Picornaviridae, and Togaviridae [4]. These features of MxA, demonstrated in vitro, make it appear as a key antiviral effector of innate immunity in the human species. Accordingly, its allelic polymorphism can be expected to affect the severity of viral diseases in humans [4]. The MxA gene (GenBank accession no. AC005612) is located on the long arm of chromosome 21 (21q22.3) and contains 17 exons over a 33-kb stretch [5, 6]. Its promoter contains three interferon-stimulated response elements (ISREs), a class II IL-6 response element, an Sp1 binding site, and several NF-kappaB binding sites [7]. To date, two single-nucleotide polymorphisms (SNPs) have been characterized. They are located in the promoter region, at positions −123 (C/A) and −88 (G/T), and affect the MxA expression level of [8-10]. A series of population-based studies have linked these SNPs to specific risks or clinical outcomes [11-17]. The flowering of such studies since the discovery of these first two SNPs highlights the crucial medical importance of MxA allelic variants as biomarkers of susceptibility or resistance to viral infections in humans. It is thus highly desirable to screen the MxA promoter and coding sequence systematically so as to inventory its allelic variants. Here our aim was to contribute to this inventory and to examine whether genotype frequencies vary among ethnic groups. We have detected many SNPs, four of which, including two non-synonymous SNPs in the coding sequence, have never been detected before (http://snp.cshl.org/).

Materials and methods

Population samples

Two hundred and sixty-seven mouth swabs (Isohelix Swab, cat. no. SK-2S) were collected from three distinct populations between 2008 and 2011. Thirty-six swabs were obtained from Asian (Chinese and Vietnamese) university students, 131 from Belgian and French students (Western Europeans), and 100 from African students (from Algeria, Libya, Cameroun, Niger, Congo, or Rwanda). Within each ethnic group, the subjects tested were randomly selected. Each swab was rubbed for 1 min against the inside of the cheek or behind the lower or upper lip and stored at 4 °C until processed. The study was approved by the local Bioethics Committee (File #PolyMxA/AC/2010).

DNA extraction and SNP detection

Genomic DNA was extracted from mouth epithelial cells with a commercially available kit (Isohelix cat. no. BEK-50). Each specimen was characterized quantitatively (Nanodrop) and qualitatively (Isohelix cat. no. DQC-50) and stored at −20 °C until used. SNPs were detected by PCR amplification of 12 successive segments of the MxA gene, followed by sequencing of the PCR products. A first step was to validate combined long-range and nested PCR amplification of the 9.8-kb gene segment comprising the promoter and exons 1–5. Then, 11 exon-specific PCR protocols were developed. Primer sequences are listed in Table 1 and the detailed characteristics of each PCR reaction are available on request. The PCR products were purified with the innuPREP DOUBLEpure kit (Analytik Jena) and sequenced on an ABI-3100 Genetic Analyzer using Big Dye terminator chemistry (Applied Biosystems). The primers listed in Online Resource #2 were used to sequence the 9.8-kb gene segment comprising the promoter and exons 1–5. Primers were designed with Netprimer [http://www.premierbiosoft.com/netprimer]. Nucleotide sequence and identity analyses were carried out, respectively, with the Chromas v.2.21 (http://www.technelysium.com.au) and BLAST programs. Sequences were aligned with GeneDoc v.2.7.000 (http://www.psc.edu/biomed/genedoc).
Table 1

Sequences of primers used to amplify MxA gene promoter and exons

Primer namePrimer sequence 5′ → 3′Annealing temperature (°C)ExonPCR product size
Long-range PCR FATCTCCCACTCACAGCCAGTTAGCC55.9Promoteur—Exon 59,631
Long-range PCR RGCAGCTGGGTGCAATTTTCCTAAAG52.6
Nested PCR FCATGGGTCTGCTTGACTCAGCCCTC57.5Promoteur—Exon 59,044
Nested PCR RCTCCCTGGGTCAACTCCTTCACCTC57.5
MxAex6FTTAGACTTATTGAAGTTGGCCGT646193
MxAex6RTCTTCCTACCACACCTGATCTGT68
MxAex7FGCTTTCAAGCGTTAGTAAGCAAA647138
MxAex7RAAAAGAAGTAGAAGGAACCGTGG66
MxAex8FTCCCAATCACAGAAAATTGAATC628155
MxAex8RGCTTCCATTCAACTTGACAGAAC66
MxAex9FCTGAGCCTATAGCTCTGCTTCTG709139
MxAex9RCTGCTCCCTTAGCAGGTCTTAGT70
MxAex10FGAGATGGGATGTCCATAACTCAA6610199
MxAex10RGGCAGTATTTTGTAATCCCCTTC66
MxAex11FGAGCTCATTCCATATCATTGTGG661179
MxAex11RATAGTCTATCAGCATTCCCCCTG68
MxAex12 + 13FGTTGTTGAATCTCAAATTGCTCC6412 + 13265
MxAex12 + 13RCCTTTAGGAAGGATTGGGTTATG66
MxAex14FACTCCCCTTCCTGAGATGACTAA6814159
MxAex14RGAGGAAAGTGCTGAAGTTTGGT64
MxAex15FGGGGTCATTTGCTTTTAAGATTC641577
MxAex15RCGTTTAAGCACTCCCTCCTTTAT66
MxAex16FGGGCTAGAAACCTGCCTTAGATA6816249
MxAex16RAGGCTAACAAGGAGGTAAACGAC68
MxAex17FTGCCTGCTTACCTTTATAGAGCA6617682
MxAex17RTATTAAGTTAGCACCGTTGGCTT64
Sequences of primers used to amplify MxA gene promoter and exons

Statistical methods

Allele and genotype frequencies were estimated by direct counting. The heterogeneity of population samples and conformity with the Hardy–Weinberg equilibrium were evaluated with Fisher’s exact test and the chi2 test. The criterion for statistical significance was P < 0.05.

Results

The promoter and the 17 exons of the MxA gene were sequenced from the genomic DNA of 267 subjects from Belgium and France (n = 131), Africa (n = 100), or Asia (n = 36). Eighteen SNPs were identified in the cohort, four of which are not listed in international databases (Table 2). The first two (−309 C/G and −101 G/A), whose chromatograms are presented (Fig. 1), are located in the promoter. They were detected in the African population, although quite rarely, since only two individuals heterozygotic at −309 and a single individual heterozygotic at −101 were identified. Two new SNPs were identified in exon 10: +15523 G/A and +15561 G/A. At position +15523, the A allele appeared very rare and exclusively in the Asian population (two GA heterozygotic individuals were detected). This rare allele encodes a protein with a Gly255Glu substitution. At position +15561, the A allele appeared very rare, having been found in only one (African) individual (who was homozygous for this allele). This rare variant encodes a protein with a Val268Met substitution.
Table 2

Synopsis of reported single nucleotide polymorphisms in human MxA gene

Genomic segmentNucleotide changeAllelesSNP IDAmino acid changeEnsemblNCBI SNPThis study
Promoter−309C/GNot listed yetND+
−159C/Ars35745218ND+
−139C/Trs34188463ND+
−123C/Ars17000900ND++
−101G/AND+
−88G/Trs2071430ND++
Exon 1+20A/Crs464138+++
Exon 5+5824C/Trs114131127++
Exon 7+10892G/Ars17000915++
Exon 9+14738C/Trs467960+++
Exon 10+15523G/ANot listed yetG/E+
+15527T/Grs55748803++
+15561G/ANot listed yetV/M+
Exon 11+17578G/Ars62623435G/R++
+17599C/Trs116233935++
Exon 12+19278G/Ars115187240++
Exon 13+19777G/Ars469390V/I+++
+19784C/Trs34717738A/V++
+19827T/Crs75157475++
+19897G/Trs35132725E/X++
Exon 14+22960T/Crs2070229+++
+23046T/Grs78721041V/G++
Exon 15+24998A/Crs75718352N/T++
Exon 16+26476G/Ars1804113V/I++
+26508A/Grs1050008+++
+26577C/Trs117998041+++
+26580G/Ars469304+++
Exon 17+32352C/Trs111867117++
+32376G/Trs2230454Q/H++
+32398C/ACOSM71731L/I+
+32537A/Grs1557370+++
+32605C/Trs2230455++
+32639C/Trs116752870++
+32640G/Ars2230456+++
+32685A/Grs1804112++
+32748A/Grs60687893+++
+32749T/Ars55992492+++
+32925G/Ars73372143+++
Fig. 1

Examples of chromatograms revealing the polymorphisms discovered in the MxA promoter region. A → D : positions −309, −123, −101 and −88, respectively

Synopsis of reported single nucleotide polymorphisms in human MxA gene Examples of chromatograms revealing the polymorphisms discovered in the MxA promoter region. A → D : positions −309, −123, −101 and −88, respectively Genotype and allele frequencies are displayed in Online Resources #4–8. A significant departure from Hardy–Weinberg equilibrium was observed in 4 out of 45 tests (P < 0.0001 in the African population for the −123 and −88 polymorphisms, P < 0.005 in the African population for the +15561 polymorphism, and P < 0.001 in the Western European population for the +32537 polymorphism). This number of significant results is no larger than might be expected to occur through chance alone. Seventeen tests showed significant differences between the three populations (P < 0.05). The C/G, A/C, A/G, and G/T allele distributions at positions −309, −123, −101, and −88, respectively, within the promoter, were similar in the three groups, with a highly dominant allele at each location (C, C, G, and G respectively). The most noticeable features detected were (i) the total absence of the −309G and −101A alleles in the Asian and Western European populations and (ii) the low prevalence of the high-MxA-producer genotypes AA (−123) and TT (−88). In the UTR-5′ region, the distribution of the C/A (+20) allele appeared significantly different among groups, the C allele being dominant in Asia and the A allele elsewhere. Within the coding region, the three most noticeable between-population differences were the absence of allele A in one (32925) or two (15523 and 32640) of the populations studied.

Discussion

In this study of polymorphisms in the MxA gene and of the corresponding allele frequencies within geographically diverse populations, we have highlighted genetic variation linked to ethnic origin. The variation of some allele frequencies was sufficient to distinguish at least one population as « different » from the others. For example, the Asian group shows lower +20A and +26580A allele frequencies than the other populations. Only in the case of the −123 and −88 polymorphisms were the allele distributions about the same throughout the three populations. The findings of this study corroborate the scant population data available. The low prevalence of the high-MxA-producer genotypes AA (−123) and TT (−88) has been noted previously [8], as has the high occurrence of the +20C allele in Asian populations [14]. We have detected four new polymorphisms, two in the coding region of MxA (one leading to a Gly255Glu substitution and the other to a Val268Met substitution in the N-terminal domain) and two in the promoter region. The available structural data are not sufficient for predicting which specific MxA functions might be altered by these variations [18]. Nevertheless, BLOSUM 62 matrix scoring of the two substitutions according to their putative impacts on protein structure [19] revealed that Gly255Glu might significantly affect MxA structure (score: -2), while Val268Met should not (score: +1). On the other hand, both new polymorphisms revealed in the MxA promoter region might significantly alter the gene’s expression pattern, since the first two polymorphisms ever identified in the MxA promoter appear to be linked to the MxA expression level, the specific risk of infection, and the clinical outcome of disease [8-10]. A highly significant difference in the distribution of −88 G/T has been observed between patients with persistent and self-limiting HBV infections [15], and the presence of the AG haplotype (−123A and −88G) in an individual appears to correlate significantly with susceptibility to HBV infection [16]. Furthermore, a lower frequency of the −88 GG genotype has been observed in self-limiting HCV infection and in nonresponders to therapy [11]. In Japanese individuals, the −88 GT genotype may confer to the host genetic susceptibility to subacute sclerosing panencephalitis [12]. Also, a significantly higher frequency of the −123A, −88T haplotype, correlating with overexpression of MxA, has been observed in multiple sclerosis [14]. As regards susceptibility to the SARS coronavirus, −123A allele carriers appear to be significantly less at risk of infection [17], a GT genotype at position −88 appears associated with increased susceptibility [20], and the GG genotype at position −88 appears to be more frequent in hypoxemic than in non-hypoxemic patients [13]. All these observations make it a priority to conduct functional testing of the new MxA promoter haplotypes revealed here and to include them in future population-based case–control studies. Of particular interest is the fact that the new −101A allele restores a near-canonical ISRE module in the promoter, which theoretically should increase MxA expression in response to interferons α, β, and λ. Below is the link to the electronic supplementary material. Supplementary material 1 (DOCX 15 kb) Supplementary material 2 (DOCX 16 kb) Supplementary material 3 (DOCX 14 kb) Supplementary material 4 (DOCX 14 kb) Supplementary material 5 (DOCX 15 kb) Supplementary material 6 (DOCX 17 kb)
  20 in total

1.  Amino acid substitution matrices from protein blocks.

Authors:  S Henikoff; J G Henikoff
Journal:  Proc Natl Acad Sci U S A       Date:  1992-11-15       Impact factor: 11.205

Review 2.  Dynamin-like MxA GTPase: structural insights into oligomerization and implications for antiviral activity.

Authors:  Otto Haller; Song Gao; Alexander von der Malsburg; Oliver Daumke; Georg Kochs
Journal:  J Biol Chem       Date:  2010-06-10       Impact factor: 5.157

3.  Identification of a single nucleotide polymorphism in the MxA gene promoter (G/T at nt -88) correlated with the response of hepatitis C patients to interferon.

Authors:  M Hijikata; Y Ohta; S Mishiro
Journal:  Intervirology       Date:  2000       Impact factor: 1.763

4.  Structure and polymorphism of the human gene for the interferon-induced p78 protein (MX1): evidence of association with alopecia areata in the Down syndrome region.

Authors:  R Tazi-Ahnini; F S di Giovine; A J McDonagh; A G Messenger; C Amadou; A Cox; G W Duff; M J Cork
Journal:  Hum Genet       Date:  2000-06       Impact factor: 4.132

Review 5.  Protective role of interferon-induced Mx GTPases against influenza viruses.

Authors:  O Haller; P Staeheli; G Kochs
Journal:  Rev Sci Tech       Date:  2009-04       Impact factor: 1.181

6.  Polymorphisms in interferon-induced genes and the outcome of hepatitis C virus infection: roles of MxA, OAS-1 and PKR.

Authors:  S Knapp; L J Yee; A J Frodsham; B J W Hennig; S Hellier; L Zhang; M Wright; M Chiaramonte; M Graves; H C Thomas; A V S Hill; M R Thursz
Journal:  Genes Immun       Date:  2003-09       Impact factor: 2.676

7.  cDNA structures and regulation of two interferon-induced human Mx proteins.

Authors:  M Aebi; J Fäh; N Hurt; C E Samuel; D Thomis; L Bazzigher; J Pavlovic; O Haller; P Staeheli
Journal:  Mol Cell Biol       Date:  1989-11       Impact factor: 4.272

8.  Influences of MxA gene -88 G/T and IFN-gamma +874 A/T on the natural history of hepatitis B virus infection in an endemic area.

Authors:  X M Peng; R X Lei; L Gu; H H Ma; Q F Xie; Z L Gao
Journal:  Int J Immunogenet       Date:  2007-10       Impact factor: 1.466

9.  Association of SARS susceptibility with single nucleic acid polymorphisms of OAS1 and MxA genes: a case-control study.

Authors:  Jing He; Dan Feng; Sake J de Vlas; Hongwei Wang; Arnaud Fontanet; Panhe Zhang; Sabine Plancoulaine; Fang Tang; Lin Zhan; Hong Yang; Tianbao Wang; Jan H Richardus; J Dik F Habbema; Wuchun Cao
Journal:  BMC Infect Dis       Date:  2006-07-06       Impact factor: 3.090

10.  Significance of the myxovirus resistance A (MxA) gene -123C>a single-nucleotide polymorphism in suppressed interferon beta induction of severe acute respiratory syndrome coronavirus infection.

Authors:  Johannes Chi-Yun Ching; Kelvin Yuen Kwong Chan; Eric Hing Leung Lee; Mei-Shu Xu; Campbell Kam Po Ting; Thomas M K So; Pak C Sham; Gabriel M Leung; Joseph S M Peiris; Ui-Soon Khoo
Journal:  J Infect Dis       Date:  2010-06-15       Impact factor: 5.226

View more
  8 in total

1.  The myxovirus resistance A (MxA) gene -88G>T single nucleotide polymorphism is associated with prostate cancer.

Authors:  Shanora Glymph; Sanjay Mandal; Ashley Evans Knowell; Fisseha Abebe; Jaideep Chaudhary
Journal:  Infect Genet Evol       Date:  2013-02-22       Impact factor: 3.342

2.  Functional Comparison of Mx1 from Two Different Mouse Species Reveals the Involvement of Loop L4 in the Antiviral Activity against Influenza A Viruses.

Authors:  Judith Verhelst; Jan Spitaels; Cindy Nürnberger; Dorien De Vlieger; Tine Ysenbaert; Peter Staeheli; Walter Fiers; Xavier Saelens
Journal:  J Virol       Date:  2015-08-19       Impact factor: 5.103

3.  Role of nucleotide binding and GTPase domain dimerization in dynamin-like myxovirus resistance protein A for GTPase activation and antiviral activity.

Authors:  Alexej Dick; Laura Graf; Daniel Olal; Alexander von der Malsburg; Song Gao; Georg Kochs; Oliver Daumke
Journal:  J Biol Chem       Date:  2015-03-31       Impact factor: 5.157

4.  Effects of allelic variations in the human myxovirus resistance protein A on its antiviral activity.

Authors:  Laura Graf; Alexej Dick; Franziska Sendker; Emanuel Barth; Manja Marz; Oliver Daumke; Georg Kochs
Journal:  J Biol Chem       Date:  2018-01-12       Impact factor: 5.157

5.  The 125th Lys and 145th Thr Amino Acids in the GTPase Domain of Goose Mx Confer Its Antiviral Activity against the Tembusu Virus.

Authors:  Shun Chen; Miao Zeng; Peng Liu; Chao Yang; Mingshu Wang; Renyong Jia; Dekang Zhu; Mafeng Liu; Qiao Yang; Ying Wu; Xinxin Zhao; Anchun Cheng
Journal:  Viruses       Date:  2018-07-06       Impact factor: 5.048

Review 6.  Mx genes: host determinants controlling influenza virus infection and trans-species transmission.

Authors:  Otto Haller; Georg Kochs
Journal:  Hum Genet       Date:  2019-11-26       Impact factor: 4.132

7.  MxA transcripts with distinct first exons and modulation of gene expression levels by single-nucleotide polymorphisms in human bronchial epithelial cells.

Authors:  Satoshi Noguchi; Minako Hijikata; Emi Hamano; Ikumi Matsushita; Hideyuki Ito; Jun Ohashi; Takahide Nagase; Naoto Keicho
Journal:  Immunogenetics       Date:  2012-11-18       Impact factor: 2.846

Review 8.  Mammalian and Avian Host Cell Influenza A Restriction Factors.

Authors:  Joe McKellar; Antoine Rebendenne; Mélanie Wencker; Olivier Moncorgé; Caroline Goujon
Journal:  Viruses       Date:  2021-03-22       Impact factor: 5.048

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.